Target Identification & HIT Discovery

Discovering the right target is often the hardest part of oncology drug development. LIDE provides a multi-platform Target ID and Validation platform, integrating the breadth of LIDE’s capabilities across functional genomic screening, drug-resistant patient models, and bioinformatics to uncover and validate novel cancer drivers.

1. CRISPR/Cas9 Screens

  • Genome-wide CRISPR/Cas9 knockout and knock-in libraries
  • Identify essential genes and synthetic lethal interactions
  • Available in both in vitro cell lines (commercial, CR, CRC, organoids) and in vivo PDX/CR models
  • Downstream readouts include growth inhibition, tumor regression, multi-omics, and immune infiltration changes

2. High-Throughput pro-siRNA Screening

  • Arrayed pro-siRNA library targets all genes expressed in a given cell population
  • Utilizes the p19 protein system to stabilize ~21-nt siRNA fragments
  • Efficient knockdown with fewer off-target effects than traditional siRNA
  • Can silence gene families or copy-number amplified genes
  • Cost-effective since E. coli is used as a production system

Advantages of LIDE’s pro-siRNA Platform

  • Represents the true transcriptome of target cells
  • Maintains efficiency with reduced off-target artifacts
  • Suitable for high-throughput phenotypic screens
  • Enables discovery of previously inaccessible or redundant gene targets

What makes LIDE’s Target ID platform unique is the ability to immediately connect new targets to clinically relevant preclinical models:

  • Drug-resistant PDX & CR Cells – resistant samples provide fertile ground for finding new vulnerabilities
  • MiniPDX® / IO-FIVE™ – rapid in vivo validation of identified targets or tool compounds in 7–14 days
  • Omics-Integrated Biomarker Discovery – WES, RNAseq, proteomics, IMC to link target biology to patient stratification
  • Orthotopic & Humanized Models – confirm gene function in immune-competent or immune-humanized contexts

Partnering Opportunities
LIDE is actively seeking collaborations and risk-sharing partnerships to validate hits and develop novel therapies.

We provide:

  • Hit-to-lead validation in vitro and in vivo
  • Access to rare or drug-resistant clinical models
  • Bioinformatics-driven target prioritization and biomarker analysis
  • Tailored study design to accelerate IND-enabling research

Request a consultation with our Scientific Engagement team ›